Funding announcement
Curlew Bio Joins MTM's Brisbane Pod
Molecule to Medicine announces Curlew Bio as the second venture in its Brisbane Pod, with Uniquest Expansion Fund backing, to develop immunological therapies for inflammatory disease.
Startup
Curlew Bio
Brisbane, QLD
Funding history
-
Accelerator
Programs: Molecule to Medicine (Brisbane Pod)
Investors
Every investor coverage indicates participated in a round Curlew Bio raised.
| Investor | Rounds | Invested |
|---|---|---|
| Molecule to Medicine | Accelerator | - |
What Curlew Bio bought
Companies Curlew Bio acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
People
Coverage
Stories naming Curlew Bio. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Unnamed stage
$1m
UQ biotech innovation partnership forges a second startup
UniQuest and Molecule to Medicine have formed Curlew Bio to develop anti-inflammatory drugs, backed by $1 million from UniQuest's Extension Fund; the article also recalls Novartis's 2015 purchase of Spinifex Pharmaceuticals.